Cogent Biosciences, Inc. (COGT) Stock Price & How to Invest

Cogent Biosciences is a Waltham, Massachusetts and Boulder, Colorado biotechnology company building precision therapies for genetically defined diseases. Its lead asset, bezuclastinib, is a tyrosine kinase inhibitor designed to hit the KIT D816V mutation and other KIT exon 17 mutations. That single molecule underpins three indications: non-advanced systemic mastocytosis (the SUMMIT trial), advanced systemic mastocytosis (APEX), and gastrointestinal stromal tumors after imatinib, where it is paired with sunitinib (the PEAK trial). Behind bezuclastinib sits an early research portfolio aimed at ErbB2, PI3K alpha, KRAS and JAK2, with CGT4255 and CGT6297 entering Phase 1 in 2026 and IND filings planned for CGT1815 and CGT1145.

The investment picture is unusually concentrated in a short window. As of October 2026 all three NDAs are accepted by the FDA: a Priority Review PDUFA date of November 30, 2026 for GIST, December 30, 2026 for non-advanced systemic mastocytosis, and June 29, 2027 for advanced systemic mastocytosis, which the FDA accepted on September 15, 2026 without plans for an advisory committee. In September the company also signed a commercial supply agreement with Hovione FarmaCiencia, one more piece of launch preparation. Cogent ended June 2026 with roughly $792 million in cash and about $244 million of debt, the second quarter net loss was about $96 million (EPS of -$0.52 against a -$0.56 estimate), and general and administrative spending has risen sharply as the commercial organization is built ahead of any approval. The stock ran from about $14 to a high near $44 over the past year and has since given back about a third of that peak. There is no product revenue, the trailing net loss is roughly $377 million, and the difference between a launch and a delay is the whole thesis.

Everything routes through one molecule, so a complete response letter, a label restriction or a safety signal on any of the three applications hits the whole company at once, and two of those decisions land within the next eleven weeks. Bezuclastinib's history includes liver enzyme elevations that shaped dosing decisions, and tolerability is exactly what prescribers weigh when an alternative already exists. In systemic mastocytosis that alternative is avapritinib, now inside Sanofi after the Blueprint Medicines acquisition, which brings launch resources Cogent cannot match. Cash of about $792 million at the end of June funds operations into 2028 on management's plan, but quarterly losses run near $96 million and a slower launch or a wider trial program means returning to equity markets; the company has already used its at-the-market program and carries about $244 million of debt, mostly convertible notes. Insider selling (one filing in late August 2026 showed about $1.7 million of shares sold) and a 25% three-month decline show that sentiment can swing well before any FDA date.

11 analysts publish price targets on COGT, averaging $55.82 against a $29.92 price as of November 2026, or +86.6%. The published targets run from $45.00 to $62.00, a moderate spread, and the ratings split 11 buy, 1 hold, 0 sell. Over the last six months there have been 2 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full COGT forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Cogent Biosciences, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Three regulatory decisions inside nine months. Bezuclastinib has an accepted NDA in second-line GIST under Priority Review with a November 30, 2026 PDUFA date, an accepted NDA in non-advanced systemic mastocytosis with a December 30, 2026 date, and an accepted NDA in advanced systemic mastocytosis with a June 29, 2027 date. The most optimistic published target, $62.00, assumes this works close to its best case.

The case against. Everything routes through one molecule, so a complete response letter, a label restriction or a safety signal on any of the three applications hits the whole company at once, and two of those decisions land within the next eleven weeks. The most pessimistic target, $45.00, is roughly what COGT is worth if this bites instead.

Read the full bull and bear case on COGT, including what would have to change to break either one. Walnut is not an investment adviser.

Yes. Cogent Biosciences, Inc. (COGT) has had one share split in the last 10 years:

• 1:4 on November 9, 2020, so every share held became 0.25 shares.

A split changes the share count and the price per share and leaves the value of a holding unchanged. Someone holding $1,000 of COGT the day before the 1:4 split held $1,000 the day after, in more shares at a proportionally lower price. Historical prices from before the date are normally shown split-adjusted, which is why a long-run chart shows no cliff.

Splits matter mainly because they make older price figures confusing to compare by hand, and because a board choosing to split is usually signalling that the price has run up far enough to feel awkward for smaller buyers. Neither is a reason to buy or sell.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Cogent Biosciences, Inc.'s investor relations page or your broker.

• Market cap: ~$5.1B
• Revenue (TTM): ~$0 (no approved product)
• Net loss (TTM): ~$377M
• Q2 2026 net loss / EPS: ~$96M / -$0.52 vs -$0.56 estimate
• Cash (Jun 30, 2026): ~$792M
• Debt: ~$244M
• Consensus 2027 revenue: ~$284M

There is no earnings multiple here because there are no earnings and no product sales, so the market is valuing probability-weighted future revenue from bezuclastinib across three indications. Net of roughly $792 million in cash and about $244 million of debt, the enterprise value sits near $4.6 billion, down from roughly $6.6 billion in the summer, which still implies the market assumes at least one approval and a credible launch. Third quarter results are expected around November 3, 2026, just ahead of the first PDUFA date, with consensus EPS near -$0.55.

Other names that sit close to COGT: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

There are three common ways to get COGT exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so COGT sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where COGT fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

COGT is a pre-revenue biotech that is one or two FDA decisions away from becoming a commercial company. The market has taken some of the optimism back out since the summer, but the valuation still assumes those decisions go its way.

Whether COGT is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is COGT a buy or a sell?, and where the stock could go from here in the COGT stock forecast.

For income investors, whether COGT pays a dividend and how the payout looks is covered in does COGT pay a dividend? And to weigh COGT against a peer, read the full side-by-side comparisons: COGT vs SNY and COGT vs NVS.